» Articles » PMID: 32194719

MicroRNA-22 Enhances Radiosensitivity in Cervical Cancer Cell Lines Via Direct Inhibition of C-Myc Binding Protein, and the Subsequent Reduction in HTERT Expression

Overview
Journal Oncol Lett
Specialty Oncology
Date 2020 Mar 21
PMID 32194719
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRs) influence the expression of their target genes post-transcriptionally and serve an important role in multiple cellular processes. The downregulation of miR-22 is associated with a poor prognosis in cervical cancer. However, the mechanisms underlying miR-22-mediated gene regulation and its function are yet to be elucidated. In the present study, the effect of miR-22 expression on the radiosensitivity of cervical cancer was investigated. First, miR-22 was either up- or downregulated to evaluate the regulation of the MYC-binding protein (MYCBP) in four cervical cancer cell lines (C-4I, SKG-II and SiHa). Notably, MYCBP expression was inversely associated with miR-22 induction. A dual-luciferase reporter gene assay revealed that miR-22 directly targets the MYCBP 3'-untranslated region. Subsequently, the level of human telomerase reverse transcriptase component (hTERT; an E-box-containing c-Myc target gene) was analyzed after the up- or downregulation of miR-22. Notably, miR-22-mediated repression of MYCBP reduced hTERT expression. In addition, the influence of miR-22 on radiosensitivity in C-4I, SKG-II and SiHa cells was examined using a clonogenic assay and in mouse xenograft models. Upregulation of miR-22 was associated with increased radiosensitivity. Furthermore, lentiviral transduction of miR-22 reduced the Ki-67 index while increasing the TUNEL index in xenograft tissue. The current findings indicate the potential utility of miR-22 in radiotherapy for cervical cancer.

Citing Articles

Screening of Hub Genes and Therapeutic Drugs in Cervical Cancer Using Integrated Bioinformatics Analysis.

Talihati Z, Abudurousuli K, Hailati S, Han M, Nuer M, Khan N J Cancer. 2025; 16(1):92-109.

PMID: 39744564 PMC: 11660142. DOI: 10.7150/jca.87027.


MicroRNAs role in telomere length maintenance and telomerase activity in tumor cells.

Bortoletto S, Nunes-Souza E, Marchi R, Ruthes M, Okano L, Tofolo M J Mol Med (Berl). 2024; 102(9):1089-1100.

PMID: 39042290 DOI: 10.1007/s00109-024-02467-z.


LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation.

Ali A, Grillone K, Ascrizzi S, Carida G, Fiorillo L, Ciliberto D Mol Ther Nucleic Acids. 2024; 35(2):102221.

PMID: 38868363 PMC: 11168481. DOI: 10.1016/j.omtn.2024.102221.


Tetrahedral framework nucleic acids-based delivery of MicroRNA-22 inhibits pathological neovascularization and vaso-obliteration by regulating the Wnt pathway.

Liu X, Xu X, Lai Y, Zhou X, Chen L, Wang Q Cell Prolif. 2024; 57(7):e13623.

PMID: 38433462 PMC: 11216936. DOI: 10.1111/cpr.13623.


The emerging role of microRNA-22 in the Leukemia: experimental and clinical implications.

Xia J, Bu C, Zhang B, Wang X, Chen Y, Li T Mol Biol Rep. 2023; 51(1):12.

PMID: 38085373 DOI: 10.1007/s11033-023-08922-3.


References
1.
Kaur A, Mackin S, Schlosser K, Wong F, Elharram M, Delles C . Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. Cardiovasc Res. 2019; 116(6):1113-1124. DOI: 10.1093/cvr/cvz302. View

2.
Zhang X, Li Y, Wang D, Wei X . miR-22 suppresses tumorigenesis and improves radiosensitivity of breast cancer cells by targeting Sirt1. Biol Res. 2017; 50(1):27. PMC: 5590131. DOI: 10.1186/s40659-017-0133-8. View

3.
Ono Y, Hayashi M, Tanabe A, Hayashi A, Kanemura M, Terai Y . Estradiol-mediated hepatocyte growth factor is involved in the implantation of endometriotic cells via the mesothelial-to-mesenchymal transition in the peritoneum. Am J Physiol Endocrinol Metab. 2015; 308(11):E950-9. DOI: 10.1152/ajpendo.00573.2014. View

4.
Yagi A, Ueda Y, Kakuda M, Tanaka Y, Ikeda S, Matsuzaki S . Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry. Cancer Res. 2019; 79(6):1252-1259. DOI: 10.1158/0008-5472.CAN-18-3109. View

5.
Wright J, Matsuo K, Huang Y, Tergas A, Hou J, Khoury-Collado F . Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019; 134(1):49-57. PMC: 7641496. DOI: 10.1097/AOG.0000000000003311. View